Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: "Nicholas P Restifo" Clear advanced filters

  • Many patients have now received various types of immunotherapy, so we asked three scientists to give their views on whether acquired resistance to immunotherapy exists in patients and the future challenges posed by immunotherapy.

    • Nicholas P. Restifo
    • Mark J. Smyth
    • Alexandra Snyder
    Reviews
    Nature Reviews Cancer
    Volume: 16, P: 121-126

  • Immune cells called cytotoxic T cells can recognize and destroy cancer cells. The finding that stem-cell-like T cells exist in tumours, at niche sites that support these cells, could aid efforts to boost anticancer immune responses.

    • Suman Kumar Vodnala
    • Nicholas P. Restifo
    News & Views
    Nature
    Volume: 576, P: 385-386

  • There is currently much interest in dissecting the mechanisms of tumor immunity. A new study shows that a subset of CD4+ T cells that produce the cytokine interleukin-9 (IL-9) mediate inhibition of melanoma growth in mice and that analogous IL-9–producing T cells are present in human skin (pages 1248–1253). Could such cells be manipulated to develop new therapeutic strategies for melanoma?

    • Weiping Zou
    • Nicholas P Restifo
    News & Views
    Nature Medicine
    Volume: 18, P: 1177-1178

  • A lot of recent research has focused on T helper 17 (TH17) cells, but their function in the tumour microenvironment has remained controversial. This Review examines the roles of TH17 cells in tumour immunity and discusses the potential of targeting this subset for cancer therapy.

    • Weiping Zou
    • Nicholas P. Restifo
    Reviews
    Nature Reviews Immunology
    Volume: 10, P: 248-256

  • Most of our understanding of immunological memory comes from studies in mice. However, these studies cannot recapitulate the exposure to numerous diverse pathogens that occurs over decades in humans. But, as reviewed here, recent studies focusing on human memory T cells are revealing important features of these cells, including subset heterogeneity and spatial compartmentalization.

    • Donna L. Farber
    • Naomi A. Yudanin
    • Nicholas P. Restifo
    Reviews
    Nature Reviews Immunology
    Volume: 14, P: 24-35

  • Engineered T cells expressing two receptors distinguish malignant cells from healthy cells even in the absence of a tumor-specific antigen.

    • Ken-ichi Hanada
    • Nicholas P Restifo
    News & Views
    Nature Biotechnology
    Volume: 31, P: 33-34

  • Adoptive immunotherapy using T cells genetically engineered to express a chimeric antigen receptor that targets CD19, a B-cell differentiation antigen, has demonstrated impressive efficacy in a range of B-lymphoid malignancies. The latest results demonstrate the potential of this approach in patients with chemotherapy-refractory diffuse large B-cell lymphoma.

    • Christopher A. Klebanoff
    • Tori N. Yamamoto
    • Nicholas P. Restifo
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 11, P: 685-686

  • This article discusses how T cells promote antitumour immunity in patients with cancer. In certain cancer types, T cell populations that are isolated from tumours and expandedin vitrocan promote cancer remission when re-infused into patients. The authors explain the pros and cons of this type of immunotherapy.

    • Nicholas P. Restifo
    • Mark E. Dudley
    • Steven A. Rosenberg
    Reviews
    Nature Reviews Immunology
    Volume: 12, P: 269-281

  • Treating cancer patients with T cell-based therapies has shown some some promise in the clinic, but not all patients respond. There could be many reasons for this, some of which might be addressed by using the best possible antitumour T cell. What are the biological properties of such a cell and can we generate one?

    • Luca Gattinoni
    • Christopher A. Klebanoff
    • Nicholas P. Restifo
    Reviews
    Nature Reviews Cancer
    Volume: 12, P: 671-684